Stephen J. Simko

<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

Marie‐Luise Berres, Karen Phaik Har Lim, Tricia Peters et al. · The Journal of Experimental Medicine · 2014 · 436 citations · Full text

Medicine, Pathobiology, Pathology +13

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Rikhia Chakraborty, Oliver Hampton, Xiaoyun Shen et al. · Blood · 2014 · 426 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Matthew Ku, Mark P. Hertzberg, Huiqiang Huang et al. · The Lancet · 2024 · 142 citations

Medicine, Hematology, Oncology +15

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

Stephen J. Simko, Huy D. Tran, Jeremy Jones et al. · Pediatric Blood & Cancer · 2013 · 136 citations

Medicine, Hematology, Oncology +16

Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis

Stephen J. Simko, Benjamin Garmezy, Harshal Abhyankar et al. · The Journal of Pediatrics · 2014 · 102 citations

Medicine, Dermatology, Pathology +12